S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.07 (+1.23%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.07 (+1.23%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.07 (+1.23%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.07 (+1.23%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
Log in

NASDAQ:ILMNIllumina Stock Price, Forecast & News

$397.66
+15.50 (+4.06 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$384.66
Now: $397.66
$401.70
50-Day Range
$336.92
MA: $370.94
$398.62
52-Week Range
$196.78
Now: $397.66
$402.14
Volume62,023 shs
Average Volume820,113 shs
Market Capitalization$58.46 billion
P/E Ratio62.62
Dividend YieldN/A
Beta0.99
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$8.56 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Employees7,700
Market Cap$58.46 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$397.66
+15.50 (+4.06 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock been impacted by COVID-19 (Coronavirus)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 61.6% and is now trading at $397.66.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Illumina?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Illumina
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Illumina
.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, April, 30th. The life sciences company reported $1.64 EPS for the quarter, beating analysts' consensus estimates of $1.25 by $0.39. The life sciences company had revenue of $859 million for the quarter, compared to analyst estimates of $857.92 million. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same period last year, the firm posted $1.60 earnings per share.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

14 brokers have issued 1 year price targets for Illumina's shares. Their forecasts range from $290.00 to $390.00. On average, they expect Illumina's stock price to reach $343.36 in the next twelve months. This suggests that the stock has a possible downside of 13.7%.
View analysts' price targets for Illumina
.

Has Illumina been receiving favorable news coverage?

News coverage about ILMN stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Illumina earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the life sciences company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Illumina
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), salesforce.com (CRM), Visa (V), Micron Technology (MU), Gilead Sciences (GILD) and Baidu (BIDU).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (1.59%), Sumitomo Mitsui Trust Holdings Inc. (0.78%), Douglas Lane & Associates LLC (0.24%), First Trust Advisors LP (0.18%), New York State Teachers Retirement System (0.13%) and Envestnet Asset Management Inc. (0.09%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Waverton Investment Management Ltd, PGGM Investments, Gateway Investment Advisers LLC, Douglas Lane & Associates LLC, Vident Investment Advisory LLC, Vident Investment Advisory LLC, and Frontier Capital Management Co. LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which major investors are buying Illumina stock?

ILMN stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, First Trust Advisors LP, Envestnet Asset Management Inc., Dock Street Asset Management Inc., CWM LLC, SG Americas Securities LLC, Oregon Public Employees Retirement Fund, and Pacer Advisors Inc..
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $397.66.

How big of a company is Illumina?

Illumina has a market capitalization of $58.46 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.